| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ASTRO calls for a new value-based reimbursement structure for radiotherapy
|
Das, Manjulika
|
|
|
23 |
10 |
p. 1244
|
artikel
|
| 2 |
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
|
Conforti, Fabio
|
|
|
23 |
10 |
p. 1287-1296
|
artikel
|
| 3 |
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
|
Lorentzen, Cathrine Lund
|
|
|
23 |
10 |
p. e450-e458
|
artikel
|
| 4 |
Correction to Lancet Oncol 2022; 23: 1297–307
|
|
|
|
23 |
10 |
p. e446
|
artikel
|
| 5 |
Correction to Lancet Oncol 2022; 23: 1124–26
|
|
|
|
23 |
10 |
p. e446
|
artikel
|
| 6 |
Correction to Lancet Oncol 2021; 22: 74–84
|
|
|
|
23 |
10 |
p. e446
|
artikel
|
| 7 |
Correction to Lancet Oncol 2022; 23: 1009–20
|
|
|
|
23 |
10 |
p. e446
|
artikel
|
| 8 |
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma
|
Cabibbo, Giuseppe
|
|
|
23 |
10 |
p. e441
|
artikel
|
| 9 |
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA
|
Jiang, Changchuan
|
|
|
23 |
10 |
p. 1240-1243
|
artikel
|
| 10 |
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma
|
Sütcüoğlu, Osman
|
|
|
23 |
10 |
p. e444
|
artikel
|
| 11 |
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma
|
Sasi, Archana
|
|
|
23 |
10 |
p. e442
|
artikel
|
| 12 |
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma
|
Chib, Sushant
|
|
|
23 |
10 |
p. e443
|
artikel
|
| 13 |
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma – Authors' reply
|
Pautier, Patricia
|
|
|
23 |
10 |
p. e445
|
artikel
|
| 14 |
Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial
|
Hui, David
|
|
|
23 |
10 |
p. 1321-1331
|
artikel
|
| 15 |
ESMO Congress 2022
|
Collingridge, David
|
|
|
23 |
10 |
p. e447
|
artikel
|
| 16 |
European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making
|
Andratschke, Nicolaus
|
|
|
23 |
10 |
p. e469-e478
|
artikel
|
| 17 |
Evolution of the joint International Atomic Energy Agency (IAEA), International Agency for Research on Cancer (IARC), and WHO cancer control assessments (imPACT Reviews)
|
Veljkovikj, Igor
|
|
|
23 |
10 |
p. e459-e468
|
artikel
|
| 18 |
HPV mRNA testing in cervical cancer screening
|
Rossi, Paolo Giorgi
|
|
|
23 |
10 |
p. e436
|
artikel
|
| 19 |
HPV mRNA testing in cervical cancer screening – Authors' reply
|
Arbyn, Marc
|
|
|
23 |
10 |
p. e437
|
artikel
|
| 20 |
HPV vaccination in south Asia: new progress, old challenges
|
The Lancet Oncology,
|
|
|
23 |
10 |
p. 1233
|
artikel
|
| 21 |
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
|
Tree, Alison C
|
|
|
23 |
10 |
p. 1308-1320
|
artikel
|
| 22 |
New combination therapy for thymic epithelial tumours
|
Shintani, Yasushi
|
|
|
23 |
10 |
p. 1237-1239
|
artikel
|
| 23 |
New evidence that air pollution contributes substantially to lung cancer
|
Gourd, Elizabeth
|
|
|
23 |
10 |
p. e448
|
artikel
|
| 24 |
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial
|
Saad, Fred
|
|
|
23 |
10 |
p. 1297-1307
|
artikel
|
| 25 |
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
|
O’Brien, Mary
|
|
|
23 |
10 |
p. 1274-1286
|
artikel
|
| 26 |
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis
|
Ecker, Brett L
|
|
|
23 |
10 |
p. 1332-1342
|
artikel
|
| 27 |
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
|
Gu, Weijie
|
|
|
23 |
10 |
p. 1249-1260
|
artikel
|
| 28 |
Tempering optimism for MRI-guided focused ultrasound therapy
|
Sutera, Philip
|
|
|
23 |
10 |
p. e438
|
artikel
|
| 29 |
Tempering optimism for MRI-guided focused ultrasound therapy – Authors' reply
|
Ehdaie, Behfar
|
|
|
23 |
10 |
p. e439
|
artikel
|
| 30 |
The silent malignant mesothelioma epidemic: a call to action
|
van Zandwijk, Nico
|
|
|
23 |
10 |
p. 1245-1248
|
artikel
|
| 31 |
Tissue-agnostic RET inhibition: can you trust your target?
|
D'Aiello, Angelica
|
|
|
23 |
10 |
p. 1235-1237
|
artikel
|
| 32 |
Treatment options for metastatic hormone-sensitive prostate cancer
|
Kostos, Louise
|
|
|
23 |
10 |
p. 1234-1235
|
artikel
|
| 33 |
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
|
Subbiah, Vivek
|
|
|
23 |
10 |
p. 1261-1273
|
artikel
|
| 34 |
Ukraine's neighbouring countries accept the burden of cancer care for refugees
|
Thallinger, Christiane
|
|
|
23 |
10 |
p. e440
|
artikel
|
| 35 |
Unusual purpura as a first sign of amyloid light chain amyloidosis
|
Li, Yufen
|
|
|
23 |
10 |
p. e479
|
artikel
|
| 36 |
US FDA issues cancer warning linked to breast implants
|
Burki, Talha Khan
|
|
|
23 |
10 |
p. e449
|
artikel
|
| 37 |
War in Ukraine creates challenges for the cancer care system in Poland
|
Didkowska, Joanna A
|
|
|
23 |
10 |
p. 1239-1240
|
artikel
|
Tijdschrift beschrijving